Cost-effectiveness of scaling up of hepatitis C screening and treatment: a modelling study in South Korea

The prices and the coverage of effective direct-acting antivirals (DAAs) to treat hepatitis C vary across countries. South Korea expanded DAAs coverage through national health insurance. This study aims to analyse the cost-effectiveness of scale-up of hepatitis C screening and treatment with DAAs in South Korea, a high-income country.

Original Source

blog comments powered by Disqus